{"id":"i-v-selexipag","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Headache"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL238804","moleculeType":"Small molecule","molecularWeight":"496.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Selexipag works by binding to the prostacyclin receptor, leading to increased levels of cyclic AMP in vascular smooth muscle cells, resulting in vasodilation and improved blood flow. This mechanism is particularly beneficial for patients with pulmonary arterial hypertension (PAH).","oneSentence":"Selexipag is a prostacyclin receptor agonist that acts as a potent vasodilator.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:19.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT03187678","phase":"PHASE3","title":"Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-12-04","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT02882425","phase":"PHASE1","title":"Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-01","conditions":"Healthy Subjects","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACT-293987"],"phase":"phase_3","status":"active","brandName":"i.v. selexipag","genericName":"i.v. selexipag","companyName":"Actelion","companyId":"actelion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selexipag is a small molecule that acts as a prostanoid IP receptor agonist. It is used to treat Pulmonary Arterial Hypertension, a condition where the blood pressure in the lungs is elevated.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}